Back to Search
Start Over
Evaluation of the efficacy of Chitosan nanoparticles based on Rosuvastatin in the treatment of acute toxoplasmosis: An In vitro and In vivo study.
- Source :
-
Microbial pathogenesis [Microb Pathog] 2024 Oct; Vol. 195, pp. 106897. Date of Electronic Publication: 2024 Aug 28. - Publication Year :
- 2024
-
Abstract
- Toxoplasma gondii (T.gondii) is an obligate intracellular protozoan that infects warm-blooded animals and has a global distribution. Acute toxoplasmosis is commonly reported in patients with acquired/congenital toxoplasmosis and immune deficiency. New methods are needed to prevent the sideffects of classical treatment. In this study, Rosuvastatin loaded chitosan nanoparticle (CH-NP-ROS) were synthesized and zeta potential and size were determined, and an MTT assay was performed to evaluate the cell toxicity on Macrophage cells (MQ) and anti-Toxoplasma activity using Trypan-blue staining by different concentrations of Rosuvastatin (ROS), and Rosuvastatin loaded chitosan nanoparticle (CH-NP-ROS). The cell viability assay demonstrated that CH-NP-ROS had lower cell toxicity (<15 %) compared to ROS (<30 %). Statistical analysis showed that CH-NP-ROS significantly killed 98.950 ± 1.344; P < 0.05) of Toxoplasma gondii tachyzoites. In vivo results of perituneal fluid showed that CH-NP significantly reduced the parasite load in the CH-NP-ROS group, compared to that in negative control group (P < 0.001). Growth inhibition rates of tachyzoites in mice receiving free ROS and CH-NP-ROS (injection and oral form) were found to be 166.125 + 4.066, 118.750 + 4.596 and 124.875 + 2.652, respectively, compared to mice in Sulfadiazine/Pyrimethamine treated group (positive control). In the infected untreated mice (control +), the mean tachyzoite counts per oil immersion field in the spleen was 8.25 respectively. The mean survival time in all the groups treated with ROS and CH-NP-ROS was longer than that in the negative control group Therefore, nanoformulation is a promising approach for the delivery and is safe for using therapeutic effects in acute toxoplasmosis.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Mice
Cell Survival drug effects
Macrophages drug effects
Macrophages parasitology
Parasite Load
Antiprotozoal Agents pharmacology
Antiprotozoal Agents therapeutic use
Disease Models, Animal
Drug Carriers
Toxoplasmosis, Animal drug therapy
Toxoplasmosis, Animal parasitology
Female
Mice, Inbred BALB C
Chitosan
Rosuvastatin Calcium pharmacology
Rosuvastatin Calcium therapeutic use
Rosuvastatin Calcium administration & dosage
Nanoparticles chemistry
Toxoplasma drug effects
Toxoplasmosis drug therapy
Toxoplasmosis parasitology
Subjects
Details
- Language :
- English
- ISSN :
- 1096-1208
- Volume :
- 195
- Database :
- MEDLINE
- Journal :
- Microbial pathogenesis
- Publication Type :
- Academic Journal
- Accession number :
- 39208959
- Full Text :
- https://doi.org/10.1016/j.micpath.2024.106897